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This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between azithro-
mycin and rifabutin in volunteers with or without human immunodeficiency virus infection. Daily dosing with
the combination of azithromycin and rifabutin was poorly tolerated, primarily because of gastrointestinal
symptoms and neutropenia. No significant pharmacokinetic interactions were found between these drugs.
Mycobacterium avium complex (MAC) disease causes signif-
icant morbidity and mortality in patients with late-stage human
immunodeficiency virus (HIV) infection (2, 4, 9). Azithromy-
cin (8, 13) and rifabutin (12) are used alone for the prevention
of disseminated MAC (DMAC) infection and in combinations
for treatment of DMAC (10, 17). Currently recommended
doses for use in combination treatment of DMAC are azithro-
mycin at 500 mg daily and rifabutin at 300 mg daily (18).
Rifabutin is an inducer of hepatic microsomal cytochrome
P-450 enzymes and is known to have significant pharmacoki-
netic interactions with several therapeutic agents, including
clarithromycin (7, 16). Pharmacokinetic interactions between
these two drugs could have important implications for the
safety and effectiveness of DMAC therapy. The current study
was designed to evaluate the tolerance of combination therapy
with azithromycin and rifabutin and the potential pharmaco-
kinetic interactions.
All subjects were at least 18 years old and provided written
informed consent before enrollment according to the institu-
tional requirements of the participating centers. Subjects were
ineligible if they had significant renal or hepatic impairment or
were receiving drugs likely to have pharmacokinetic interac-
tions with the study drugs. Drugs likely to interact with the
study agents were to be avoided during the study, if possible.
The study initially evaluated high-dose regimens (azithromycin
at 1,200 mg daily and rifabutin at 600 mg daily) and enrolled
only HIV-infected persons. However, because of a high rate of
intolerance and slow enrollment, the protocol was modified to
evaluate low-dose regimens (azithromycin at 600 mg daily and
rifabutin at 300 mg daily) and to allow the enrollment of
HIV-seronegative volunteers to increase the accrual rate. Sub-
jects were initially randomized equally to one of two high-dose
regimens (A or B) and later to one of two low-dose regimens
(C or D). Regimen A and C subjects received azithromycin on
days 1 to 14 and the combination of azithromycin and rifabutin
on days 15 to 42. Regimen B and D subjects received rifabutin
on days 1 to 14 and the combination of rifabutin and azithro-
mycin on days 15 to 42. Subjects were instructed to take
azithromycin 1 h before or 2 h after a meal (alone or in
combination) and to take both drugs at the same time. All
HIV-infected patients had CD41 cell counts of ,200 cells/
mm3 and were receiving stable antiretroviral therapy. Clinical
evaluations and hematologic and biochemical profiles were
repeated every 2 weeks through day 56. Subjects experiencing
a possible drug-related adverse event greater than or equal to
grade 3, as defined by the Division of AIDS Table for Grading
Severity of Adult Adverse Experiences, permanently discon-
tinued the study drug, as did subjects who developed lower-
grade adverse events, at the investigator’s discretion or the
subject’s request. Only data for subjects who completed the
study evaluations have been included in the pharmacokinetic
analyses.
Pharmacokinetic sampling was performed on days 14, 15,
and 42. Subjects fasted for 12 h before and 2 h after study drug
administration. Samples for pharmacokinetic analysis were ob-
tained predose and at 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, and 24 h
(also at 1.5, but not 0.75, h when receiving rifabutin only) after
dosing and also at 36, 48, 72, and 96 h on days 42 to 46. All
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plasma concentrations were determined using validated high-
performance liquid chromatography techniques (11, 15) by
Pfizer Central Research for azithromycin (between-day stan-
dard deviations were ,4%; linear range, 10 to 2,000 ng/ml)
and Harris Laboratories for rifabutin and 25-O-desacetyl-ri-
fabutin (between-day coefficients of variation were #10% for
both and linear ranges were 5 to 500 and 2.5 to 250 ng/ml,
respectively). Values exceeding the linear range were diluted
and reassayed with validation for lack of dilution effect by
inclusion of appropriate standards.
Based on coefficients of variation provided by the drug man-
ufacturers, a sample size of 14 evaluable subjects receiving
each regimen was projected to provide 85% power (a 5 0.05)
for detecting a $50% change in the area under the plasma
concentration-time curve from time zero to 24 h (AUC0–24).
LAGRAN software was used to compute AUC0–24 at steady
state (14). Maximum drug concentration (Cmax) and time to
Cmax (Tmax) were determined by inspecting interpolated
curves. For drugs introduced on day 15, AUC0–` (AUC from
time zero to infinity) was calculated as AUC0–Cn 1 Cn/lz,
where Cn is the concentration at the last measurable time
point. The terminal elimination rate constant, lz, was deter-
mined by fitting a log linear regression to the last four time
points of the terminal phase, but in cases of a delayed Tmax,
three points were used. The means of the percent changes in
pharmacokinetic parameters for each subject in each arm were
compared using two-sample t tests.
Subjects were enrolled at seven study sites between March
1993 and October 1994. The baseline characteristics of subjects
randomized to the high- and low-dose regimens are shown in
Table 1. No significant differences in baseline characteristics
were found between the pairs of randomization groups receiv-
ing either the high- or low-dose regimens (all P values of
.0.20). Of the 19 subjects (all HIV seropositive) in the high-
dose regimen, 9 completed the study evaluations. Four subjects
experienced adverse events requiring study drug termination,
five discontinued therapy for lower grade adverse events, and
one developed Pneumocystis carinii pneumonia. Of 31 subjects
including the low-dose regimen, 17 (receiving 5 of the 6 HIV-
positive subjects) completed the study evaluations. One subject
never returned after the first visit, eight developed adverse
events requiring treatment termination, and five discontinued
study drugs for less-serious adverse events. Seven subjects, all
receiving the high-dose regimens, received antifungal azoles at
some time during the study, but only three of these subjects
completed the pharmacokinetic evaluations.
The most frequent adverse events occurring in the high-dose
and low-dose groups are listed in Table 2. All subjects prema-
turely discontinuing the study drug did so during combination
therapy, except for one who developed grade 3 neutropenia
while receiving high-dose rifabutin alone. Neutropenia (abso-
lute count, ,1,500 cells/mm3) was the most frequently re-
ported adverse event, occurring among 33 of 50 subjects
(66%). These episodes included seven grade 3 (500 to 750
cells/mm3) and one grade 4 (,500 cells/mm3) neutropenia
TABLE 1. Baseline characteristics of subjects assigned to receive the high- and low-dose regimens
Characteristic










Male 19 9 19 13
Female 0 0 12 4
Race (n)
White 17 7 28 15
Black 1 1 1 1
Other 1 1 2 1
Mean age, yr (SD) 38.7 (10.6) 38.7 (12.4) 36.4 (11.7) 35.1 (13.6)
Mean wt, kg (SD) 70.0 (10.3) 69.9 (7.7) 73.4 (15.6) 77.3 (15.6)
Mean ANC,d cells/mm3 (SD) 1,854 (578) 2,088 (467) 3,775 (1,518) 3,389 (1,629)
a All subjects were HIV seropositive.
b Six subjects were HIV seropositive.
c Five subjects were HIV seropositive.
d ANC, absolute neutrophil count.



















Neutropenia 9 (47) 5 (26) 16 (55) 3 (10)
Nausea 15 (79) 0 (0) 17 (59) 1 (3)
Diarrhea 13 (68) 0 (0) 13 (45) 0 (0)
Fever 4 (21) 0 (0) 7 (24) 2 (7)
Fatigue 13 (68) 1 (5) 18 (62) 2 (7)
Headache 12 (63) 1 (5) 15 (52) 2 (7)
Peripheral neuropathy 6 (32) 0 (0) 3 (10) 0 (0)
Allergic reaction 5 (26) 0 (0) 5 (17) 0 (0)
Myalgia 1 (5) 0 (0) 6 (21) 3 (10)
Skin rash 5 (26) 0 (0) 6 (21) 1 (3)
a Azithromycin at 1,200 mg daily and rifabutin at 600 mg daily.
b Azithromycin at 600 mg daily and rifabutin at 300 mg daily.
c General toxicity grade definitions: grade 1, mild; grade 2, moderate; grade 3,
severe; grade 4, life-threatening.
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events. In the low-dose groups, eight subjects had decreases of
.1,000 cells/mm3 (four of these had decreases of .2,000 cells/
mm3), and significant mean decreases in neutrophils occurred
during the initial 14 days of monotherapy with either azithro-
mycin (989 cells/mm3, P 5 0.02) or rifabutin (1,389 cells/mm3,
P , 0.01). Low-grade nausea, diarrhea, fatigue, and headache
were also common, and most subjects had more than one type
of event. The type and frequency of adverse events were sim-
ilar in the high- and low-dose regimens and in HIV-positive
and -negative subjects and occurred primarily during the com-
bination phase. There were no statistically significant differ-
ences in the baseline characteristics of subjects who completed
FIG. 1. Changes in the AUC0–24 of azithromycin (A), rifabutin (B), and 25-O-descetyl-rifabutin (C) for individual subjects between days 14 and
42.
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the study compared to those who did not complete the study
within the high- and low-dose groups.
Large reversible decreases in leukocyte counts have been
observed in non-HIV-infected patients with pulmonary MAC
disease treated with combinations including rifabutin (6).
Apseloff et al. (1) observed severe neutropenia (,1,000 cells/
mm3) in 9 of 18 healthy volunteers receiving 300 mg daily of
rifabutin alone (1 of 6) or in combination with azithromycin at
250 mg daily (4 of 6) or clarithromycin at 500 mg twice daily (4
of 6) after 10 to 14 days. Significant decreases in neutrophils
occurred during the 14 days of monotherapy with either rifabu-
tin or azithromycin among both HIV-seropositive and -sero-
negative subjects in the current study. While neutropenia is a
known side effect of rifabutin, the large decreases in neutro-
phils associated with azithromycin monotherapy in this study
have not been previously reported. The magnitude of neutro-
phil decline after 14 days of azithromycin or rifabutin mono-
therapy was not statistically associated with measurements of
systemic exposure for either study drug.
The mean AUC0–24, Cmax, and Tmax values for azithromycin,
rifabutin, and 25-O-desacetyl-rifabutin on study days 14, 15,
and 42 are presented in Table 3. None of the mean percent
changes in the pharmacokinetic parameters for azithromycin,
rifabutin, or 25-O-desacetyl rifabutin occurring between days
14 and 42 were significant (all P values were $0.13) For low-
dose regimen C, the mean percent change in azithromycin
AUC0–24 between days 14 and 42 was 121% (P 5 0.13), and
none of the nine individual azithromycin AUC0–24 estimates
decreased by .25% between days 14 and 42 (Fig. 1). For
regimen D, the mean percent change in rifabutin AUC0–24
between days 14 and 42 (25%) was not significant, and only
one of the eight individual rifabutin AUC0–24 estimates in-
creased by .25% (45%) between days 14 and 42. The mean
percent change in the AUC0–24 values of 25-O-desacetyl-ri-
fabutin observed between days 14 and 42 was also not signifi-
cant. Among the mean percent changes in pharmacokinetic
parameters between days 14 and 42 for either the high- or
low-dose regimes, only those for rifabutin and 25-O-desacetyl
rifabutin in high-dose regimen B exceeded 25%. Since all the
P values for these changes were .0.20, these differences most
likely reflected the wide variation in individual values among
the small sample (n 5 5).
The observed pharmacokinetic parameters are consistent
with those reported in previous studies of rifabutin (7, 16) and
azithromycin (5). The current pharmacokinetic analysis indi-
cates that neither rifabutin nor azithromycin had a significant
effect on the steady-state levels of the other drug. The data for
the low-dose regimens strongly support the absence of any
clinically relevant pharmacokinetic interactions between these
drugs at the highest dosages currently used in clinical practice.
Based on the actual number of evaluable subjects and observed
standard deviations in the low-dose groups, mean changes of
$35% in azithromycin AUC0–24 and $29% in rifabutin
AUC0–24 could be detected with 80% power. However, the
possibility of selection bias caused by the high rate of intoler-
ance must be recognized. Subjects not completing day 42 study
evaluations were not included in the pharmacokinetic analyses,
and intolerance to the combination study regimens could have
been related to pharmacokinetic interactions resulting in in-
creased drug concentrations. These results indicating the ab-
sence of significant pharmacokinetic interactions between
azithromycin and rifabutin are consistent with other reported
findings. In a study of groups of six volunteers assigned to
receive azithromycin at 250 mg daily, rifabutin at 300 mg daily,
or both drugs for 14 days, the mean azithromycin and rifabutin
concentrations in serum at day 10 did not differ significantly
between the groups receiving one of these drugs alone and the
group receiving the combination (1). However, pharmacoki-
netic analyses could not be completed. Also, among HIV-
seronegative patients receiving azithromycin to treat mycobac-
terial lung disease, azithromycin concentrations in serum
measured during monotherapy were apparently comparable to
concentrations observed after the addition of rifabutin (3). In
summary, neither azithromycin nor rifabutin appears to have a
significant effect on the pharmacokinetics of the other. How-
ever, this combination should not be a first-choice option for
treatment or prevention of MAC infections because of poor
tolerance.
This study, designated DATRI 001B, was supported by the Division
of AIDS Treatment Research Initiative (DATRI) Program, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, Md., contract no. NO1-AI-15123, and the Division
of Acquisition Management, Program Support Center, HHS contract
no. 282-97-0015, task order number 21.
Azithromycin was provided as 300-mg tablets by Pfizer, Inc. (New
York, N.Y.), and rifabutin was provided as 150-mg capsules by Adria
Laboratories (currently Pharmacia & Upjohn, Kalamazoo, Mich.). We
thank volunteers who participated in this study, P. K. Narang (Phar-
macia & Upjohn) and Michael Dunne (Pfizer Central Research) for
helpful review and comments during the conduct and analysis of the
study, and statistical programmer David Chang (Westat).
REFERENCES
1. Apseloff, G., G. Foulds, L. LaBoy-Goral, S. Willavize, and J. Vincent. 1998.
Comparison of azithromycin and clarithromycin in their interactions with
rifabutin in healthy volunteers. J. Clin. Pharmacol. 38:830–835.
2. Benson, C. 1994. Disseminated Mycobacterium avium complex disease in
patients with AIDS. AIDS Res. Hum. Retrovir. 10:913–916.
3. Brown, B. A., D. E. Griffith, W. Girard, J. Levin, and R. J. Wallace, Jr. 1997.
Relationship of adverse events to serum drug levels in patients receiving
high-dose azithromycin for mycobacterial lung disease. Clin. Infect. Dis.
24:958–964.
4. Chin, D. P., A. L. Reingold, E. N. Stone, E. Vittinghoff, C. R. Horsburgh, Jr.,
E. M. Simon, D. M. Yajko, W. K. Hadley, S. M. Ostroff, and P. C. Hopewell.
1994. The impact of Mycobacterium avium complex bacteremia and its treat-
ment on survival of AIDS patients—a prospective study. J. Infect. Dis.
170:578–584.
5. Foulds, G., R. M. Shepard, and R. B. Johnson. 1990. The pharmacokinetics
of azithromycin in human serum and tissues. J. Antimicrob. Chemother.
25(Suppl. A):73–82.
6. Griffith, D. E., B. A. Brown, and R. J. Wallace, Jr. 1996. Varying dosages of
rifabutin affect white blood cell and platelet counts in human immunodefi-
ciency virus-negative patients who are receiving multidrug regimens for
pulmonary Mycobacterium avium complex disease. Clin. Infect. Dis. 23:1321–
1322.
7. Hafner, R., J. Bethel, M. Power, B. Landry, M. Banach, L. Mole, H. C.
Standiford, S. Follansbee, P. Kumar, R. Raasch, D. Cohn, D. Mushatt, and
G. Drusano. 1998. Tolerance and pharmacokinetic interactions of rifabutin
and clarithromycin in human immunodeficiency virus-infected volunteers.
Antimicrob. Agents Chemother. 42:631–639.
8. Havlir, D. V., M. P. Dube, F. R. Sattler, D. N. Forthal, C. A. Kemper, M. W.
Dunne, D. M. Parenti, J. P. Lavelle, A. C. White, Jr., M. D. Witt, S. A.
Bozzette, and J. A. McCutchan. 1996. Prophylaxis against disseminated My-
cobacterium avium complex with weekly azithromycin, daily rifabutin, or
both. N. Engl. J. Med. 335:392–398.
9. Horsburgh, C. R., Jr., J. A. Havlik, D. A. Ellis, E. Kennedy, S. A. Fann, R. E.
Dubois, and S. E. Thompson. 1991. Survival of patients with acquired im-
mune deficiency syndrome and disseminated Mycobacterium avium complex
infection with and without antimycobacterial chemotherapy. Am. Rev. Re-
spir. Dis. 144:557–559.
10. Koletar, S. L., A. Berry, M. Cynamon, J. Jacobson, J. Currier, R. Mac-
Gregor, M. Dunne, and D. Williams. 1999. Azithromycin as treatment for
1576 NOTES ANTIMICROB. AGENTS CHEMOTHER.
disseminated Mycobacterium avium complex in AIDS patients. Antimicrob.
Agents Chemother. 43:2869–2872.
11. Lewis, R. C., N. Z. Hatfield, and P. K. Narang. 1991. A sensitive method for
quantitation of rifabutin and its desacetyl metabolite in human biological
fluids by high-performance liquid chromatography (HPLC). Pharm. Res.
8:1434–1440.
12. Nightingale, S. D., D. W. Cameron, F. M. Gordin, P. M. Sullam, D. L. Cohn,
R. E. Chaisson, L. J. Eron, P. D. Sparti, B. Bihari, D. L. Kaufman, et al.
1993. Two controlled trials of rifabutin prophylaxis against Mycobacterium
avium complex infection in AIDS. N. Engl. J. Med. 329(12):828–833.
13. Oldfield, E. C., III, W. J. Fessel, M. W. Dunne, G. Dickinson, M. R. Wallace,
W. Byrne, R. Chung, K. F. Wagner, S. F. Paparello, D. B. Craig, G. Melcher,
M. Zajdowicz, R. F. Williams, J. W. Kelly, M. Zelasky, L. B. Heifets, and
J. D. Berman. 1998. Once weekly azithromycin therapy for prevention of
Mycobacterium avium complex infection in patients with AIDS: a random-
ized, double-blind, placebo-controlled multicenter trial. Clin. Infect. Dis.
26:611–619.
14. Rocci, M. L., Jr., and W. J. Jusko. 1983. LAGRAN program for area and
moments in pharmacokinetic analysis. Comput. Programs Biomed. 16:203–
216.
15. Shepard, R. M., G. S. Duthu, R. A. Ferraina, and M. A. Mullins. 1991.
High-performance liquid chromatographic assay with electrochemical detec-
tion for azithromycin in serum and tissues. J. Chromatogr. 565:321–337.
16. Skinner, M. H., M. Hsieh, J. Torseth, D. Pauloin, G. Bhatia, S. Harkonen,
T. C. Merigan, and T. F. Blaschke. 1989. Pharmacokinetics of rifabutin.
Antimicrob. Agents Chemother. 33:1237–1241.
17. Sullam, P. M., F. M. Gordin, and B. A. Wynne. 1994. Efficacy of rifabutin in
the treatment of disseminated infection due to Mycobacterium avium com-
plex. Clin. Infect. Dis. 19:84–86.
18. U.S. Public Health Service/Infectious Diseases Society of America Preven-
tion of Opportunistic Infections Working Group. 1999. USPHS/IDSA guide-
lines for the prevention of opportunistic infections in persons infected with
human immunodeficiency virus. Morb. Mortal. Wkly. Rep. 48:1–66.
VOL. 45, 2001 NOTES 1577
